inositol has been researched along with linagliptin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araki, E; Dugi, KA; Gong, Y; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; von Eynatten, M; Watada, H; Woerle, HJ | 1 |
| Araki, E; Dugi, K; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; Thiemann, S; von Eynatten, M; Watada, H; Woerle, HJ | 1 |
| Cheetham, SC; Headland, KR; Jones, RB; Klein, T; Mark, M; Vickers, SP | 1 |
| Ai, M; Fujimoto, S; Fujitani, Y; Gosho, M; Hirose, T; Hiyoshi, T; Mita, T; Okada, Y; Satoh, H; Takahashi, K; Watada, H | 1 |
| Ihana-Sugiyama, N; Kakei, M; Noda, M; Sugiyama, T; Tsujimoto, T; Yamamoto-Honda, R | 1 |
| Hirai, H; Hiyoshi, T; Inoue, I; Kuribayashi, S; Moriya, C; Ohira, T; Satoh, H; Seino, H; Watada, H | 1 |
| Akita, E; Chimori, H; Fujitani, Y; Gosho, M; Inoue, I; Kurozumi, A; Mita, T; Okada, Y; Satoh, H; Shiraiwa, T; Watada, H | 1 |
| Inoue, T; Koyama, T; Node, K; Otsuka, Y; Oyama, JI; Sakuma, M; Tanaka, A; Toyoda, S; Yoshida, H | 1 |
| Ai, M; Fujimoto, S; Fujitani, Y; Gosho, M; Goto, H; Hirose, T; Hiyoshi, T; Ishii, H; Kuroda, H; Matsubara, T; Mita, T; Nishimura, H; Okada, Y; Satoh, H; Takahashi, K; Watada, H | 1 |
| Bhansali, A; Bhansali, S; Bhat, K; Kurpad, AV; Parthan, G; Walia, R | 1 |
8 trial(s) available for inositol and linagliptin
| Article | Year |
|---|---|
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Inositol; Japan; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2012 |
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Time Factors | 2013 |
Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Inositol; Japan; Linagliptin; Male; Middle Aged; Postprandial Period; Retrospective Studies; Time Factors; Young Adult | 2016 |
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin, Long-Acting; Isoindoles; Linagliptin; Male; Metformin; Middle Aged; Postprandial Period | 2017 |
Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Monitoring; Female; Humans; Hypoglycemic Agents; Inositol; Japan; Linagliptin; Male; Middle Aged | 2017 |
Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Lipids; Male; Middle Aged; Postprandial Period; Treatment Outcome | 2018 |
Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Topics: Activities of Daily Living; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Male; Middle Aged; Quality of Life; Treatment Outcome | 2018 |
Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period | 2018 |
2 other study(ies) available for inositol and linagliptin
| Article | Year |
|---|---|
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Hypoglycemic Agents; Inositol; Linagliptin; Male; Peptides; Purines; Quinazolines; Rats; Rats, Zucker; Treatment Outcome; Venoms | 2014 |
Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Male; Middle Aged; Pilot Projects; Prognosis; Prospective Studies; Vasodilation | 2018 |